Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy ...

Standard bioassays often fall short when evaluating T cell engagers due to their diverse mechanisms of actions (MOAs) and ...

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic ...

MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Researchers at the Medical University of Vienna have uncovered how a little-studied protein, TRAT1 (T Cell Receptor ...

Researchers at the Institut Pasteur and Inserm have developed a novel triple-therapy that reprograms how B cell cancers ...

在肿瘤免疫治疗领域，免疫检查点抑制剂（ICI）尤其是PD-1/PD-L1阻断剂，已在多种癌症类型中展现出显著的临床效益。然而，仍有大量患者对ICI治疗无响应或产生耐药性，其背后的机制尚未完全阐明。近年来研究表明，肿瘤微环境（TME）中的代谢应激是导致 ...

The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...